Table 2. Study characteristics of the clinical trials of minocycline on ischemic stroke.

tPA: tissue plasminogen activator, mg: miligrams, IV: intravenous

Study, year of publication	Drug	Country	Study Design	Number of patients in Treatment group	Number of patients Control	Dose, duration, route, and onset of symptoms
Switzer et al. (2011) [10]	Minocycline	United States	This was a phase 3, multicenter, non-randomized, double-blind, placebo-control trial. A separate cohort that did not receive minocycline was used.	60	44	Four doses (3.0, 4.5, 6.0, 10.0 mg/kg), over one hour every 12 hours for three days, IV, within six hours of symptom onset   If the subject received tPA, the baseline sample was taken at the moment of tPA administration.
Amiri-Nikpour et al. (2014) [4]	Minocycline	Iran	Open-label evaluator-blinded trial	26	27	200 mg, once daily for five days, oral route, 6-24 hours from the onset of symptoms.
Kohler et (2013) al.  [7]	Minocycline	Australia	This was a clinical trial, multicenter prospective randomized open-label blinded end point	47	48	100 mg, 12 hours for five doses, IV, within 24 hours of onset symptoms
Padma Srivastava et al.  (2012)[10]	Minocycline	India	Randomized single-blinded open-label study	23	27	200 mg/day for five days, oral, 6-24 of the onset of symptoms   The control group received oral vitamin B capsules.
Lampl et al. (2007) [11]	Minocycline	United States	Randomized, open- label, evaluator-blinded clinical trial.	74	77	200 mg, for five days, oral, within 6-24 of onset of symptoms.